Expert Rev Clin Pharmacol. 2024 Aug 22. doi: 10.1080/17512433.2024.2396119. Online ahead of print.
ABSTRACT
INTRODUCTION: Pediatric pulmonary hypertension is a rare condition. Survival remains poor in the current management era. There is a lack of data regarding the medical management of pediatric pulmonary hypertension and most pulmonary vasodilators are used off-label in children.
AREAS COVERED: Pediatric pulmonary hypertension clinical trials’ design and realization faces many hurdles, including poor recruitment, limited available pharmacologic and physiologic data in children of various ages, ethical issues, and the lack of validated trial endpoint. Innovative clinical trial designs have emerged and may allow us to overcome some of these issues. Extrapolation of adult data to children, with additional pharmacokinetic and safety data, remains extremely important and valid in etiologies where the pediatric and the adult pathophysiologies are believed to be similar.
EXPERT OPINION: Close collaboration between sponsors, regulators, patients, caregivers, physicians and researchers is necessary to develop efficacious and safe drugs for pediatric pulmonary hypertension. The increasing involvement of patients’ and caregivers’ participation in the development of clinical trials should help shape future research that is feasible and meaningful to the patients.
PMID:39171351 | DOI:10.1080/17512433.2024.2396119
